Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
testosterone cypionate + lutetium Lu 177 vipivotide tetraxetan
- Development stage
- Phase 2
- Lead developer
- Novartis
- Modality
- Antibody-Radionuclide Conjugates → Antibody Conjugates → Antibody-Based Therapeutics, Beta-minus Emitters → Radiopharmaceuticals, Gamma Emitters → Radiopharmaceuticals, Small Molecules, Peptides
- Administration
- Intramuscular, Intravenous
01
Overview
testosterone cypionate + lutetium Lu 177 vipivotide tetraxetan is an experimental combination regimen being evaluated by the H. Lee Moffitt Cancer Center and Research Institute for the treatment of metastatic castration-resistant prostate cancer (mCRPC). This sequential therapy utilizes high-dose testosterone cypionate (400 mg), a strategy known as Bipolar Androgen Therapy (BAT), to potentially upregulate the expression of Prostate-Specific Membrane Antigen (PSMA) on tumor cells. This priming step is followed by the administration of lutetium Lu 177 vipivotide tetraxetan (PSMA-617), a targeted radioligand therapy. PSMA-617 consists of a ligand that binds with high affinity to PSMA, a linker, and a radioactive payload, Lutetium-177. Upon binding, the drug is internalized, delivering concentrated beta-particle radiation to the cancer cells, resulting in DNA damage and cell death. The combination aims to overcome resistance and enhance the therapeutic index of radioligand therapy in patients with advanced prostate cancer.
- Other names
- 177Lu-PSMA-617Lutetium Lu 177 vipivotide tetraxetanTestosterone cypionate
02
Targets
PSMA (Prostate-specific membrane antigen)AR (Adrenergic receptors)
Beyond the preview
Go deeper on testosterone cypionate + lutetium Lu 177 vipivotide tetraxetan.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on testosterone cypionate + lutetium Lu 177 vipivotide tetraxetan.